Sumary of Time in range — not HbA1c — should guide most diabetes treatment decisions:
- September 12, 2021 3 min read Source/Disclosures Published by: Source: Grunberger G.
- “Hopefully, soon it will also become standard for people prescribed any insulin and sulfonylurea therapy — those at risk for hypoglycemia — and eventually replace finger sticking, just as finger sticks superseded urine tests.
- In one of the first studies to assess risk for diabetes outcomes associated with time in range, published in Diabetes Care in 2018, researchers assessed time in range among hospitalized patients with type 2 diabetes using blinded CGM.
- In a study published in Diabetes Care in 2019, researchers evaluated the associations of time in range with development or progression of retinopathy and microalbuminuria using the Diabetes Control and Complications Trial data set — calculating time in range from finger sticks —to validate its use as an outcome measure.
- In that study, researchers found time in range was “strongly associated” with the risk for microvascular complications and should be an acceptable endpoint for clinical trials.